Dashboard
1
Poor Management Efficiency with a low ROCE of 0.02%
- The company has been able to generate a Return on Capital Employed (avg) of 0.02% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -9.16% and Operating profit at 20.13% over the last 5 years
3
With a fall in Net Sales of -19.57%, the company declared Very Negative results in Mar 25
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 640 Million (Micro Cap)
40.00
NA
0.00%
0.82
0.89%
0.36
Revenue and Profits:
Net Sales:
314 Million
(Quarterly Results - Jun 2025)
Net Profit:
34 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.98%
0%
16.98%
6 Months
-53.56%
0%
-53.56%
1 Year
-87.27%
0%
-87.27%
2 Years
-86.61%
0%
-86.61%
3 Years
-82.54%
0%
-82.54%
4 Years
-82.51%
0%
-82.51%
5 Years
-77.54%
0%
-77.54%
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.16%
EBIT Growth (5y)
20.13%
EBIT to Interest (avg)
-1.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.83
Sales to Capital Employed (avg)
0.55
Tax Ratio
21.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.02%
ROE (avg)
0.02%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
0.36
EV to EBIT
80.41
EV to EBITDA
30.79
EV to Capital Employed
0.65
EV to Sales
1.51
PEG Ratio
0.34
Dividend Yield
NA
ROCE (Latest)
0.81%
ROE (Latest)
0.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
314.20
313.00
0.38%
Operating Profit (PBDIT) excl Other Income
68.40
-46.50
247.10%
Interest
16.00
17.20
-6.98%
Exceptional Items
0.00
0.00
Consolidate Net Profit
33.60
-65.80
151.06%
Operating Profit Margin (Excl OI)
172.20%
-194.20%
36.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.38% vs -0.92% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 151.06% vs -359.06% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,578.10
2,225.80
-29.10%
Operating Profit (PBDIT) excl Other Income
155.10
14.90
940.94%
Interest
77.40
77.00
0.52%
Exceptional Items
-0.80
0.10
-900.00%
Consolidate Net Profit
77.00
-74.50
203.36%
Operating Profit Margin (Excl OI)
65.30%
-14.60%
7.99%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -29.10% vs 10.63% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 203.36% vs 4.85% in Dec 2023
About Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. 
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






